摘要
目的探讨注射用硫普罗宁联合注射用促肝细胞生长素治疗慢性乙型肝炎的临床效果。方法选取2014年6月—2015年6月上海市奉贤区中心医院收治的慢性乙型肝炎患者106例,随机分为对照组和治疗组,每组各53例。所有患者均给予常规治疗,对照组给予注射用促肝细胞生长素100~120 mg,加入5%葡萄糖注射液250 m L中静脉滴注,1次/d。治疗组在对照组的基础上给予注射用硫普罗宁0.2 g,加入5%葡萄糖注射液250 m L中静脉滴注,1次/d。两组患者均连续治疗1个月。观察两组患者的临床疗效,检测并比较两组患者治疗前后的肝功能指标和肝纤维化指标。结果治疗后,治疗后,对照组和治疗组总有效率分别为81.1%、96.2%,两组总有效率比较差异具有统计学意义（P〈0.05）。治疗后两组血清丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶（AST）、总胆红素（TBIL）、谷氨酰转肽酶（GGT）水平均显著降低,同组治疗前后差异具有统计学意义（P〈0.05）。与对照组比较,治疗后治疗组血清ALT、AST、TBIL、GGT水平均显著低于对照组,差异具有统计学意义（P〈0.05）。治疗后两组血清透明质酸（HA）、层黏连蛋白（LN）、Ⅲ型前胶原（PcⅢ）、Ⅳ型胶原（IV-C）水平均较治疗前显著降低,差异具有统计学意义（P〈0.05）。与对照组比较,治疗后治疗组血清HA、LN、PCⅢ、IV-C水平均显著低于对照组,差异具有统计学意义（P〈0.05）。结论注射用硫普罗宁联合注射用促肝细胞生长素治疗慢性乙型肝炎具有较好的临床疗效,能够显著改善肝功能,减轻肝纤维化的程度。
Objective To investigate the clinical effect of Tiopronin for injection combined with Hepatocyte Growth-promoting Factor for injection in treatment of chronic hepatitis B. Methods Patients（106 cases） with chronic hepatitis B in Shanghai Fengxian District Central Hospital from June 2014 to June 2015 were randomly divided into control and treatment groups, and each group had 53 cases. All patients in the two groups were treated with hypoglycemic therapy. The patients in the control group were iv administered with Hepatocyte Growth-promoting Factor for injection, 100 — 200 mg dissolving with 5% glucose injection 250 m L, once daily. The patients in the treatment group were iv administered with Tiopronin for injection at the basis of the control group, 0.2 mg dissolving with 5% glucose injection 250 m L, once daily. The patients in two groups were treated for 1 month. The clinical efficacy of the two groups was observed, and then the indexes of liver function and liver fibrosis of two groups before and after the treatment were detected and compared. Results After 1 month of treatment, the efficacies in the control and treatment groups were 81.1% and 96.2%, respectively, and there were differences between two groups（P〈0.05）. After treatment, the levels of ALT, AST, TBIL, and GGT in two groups were significantly decreased, and the difference was statistically significant in the same group（P〈0.05）. And these indicators in treatment group were lower than those in the control group, with significant difference between two groups（P〈0.05）. After treatment, the levels of HA, LN, PCⅢ, and IV-C in two groups were obviously decreased, and the difference was statistically significant in the same group（P〈0.05）. And these indicators in treatment group were lower than those in the control group, with significant difference between two groups（P〈0.05）. Conclusion Tiopronin for injection combined with Hepatocyte Growth-promoting Factor for injection has good clinical effect in treatment of chronic hepatitis B, which can obviously improve liver function and relief the degree of liver fibrosis.
出处
《现代药物与临床》
CAS
2016年第1期66-69,共4页
Drugs & Clinic
关键词
注射用硫普罗宁
注射用促肝细胞生长素
慢性乙型肝炎
肝功能
肝纤维化
Tiopronin for injection
Hepatocyte Growth-promoting Factor for injection
chronic hepatitis B
liver function
liver fibrosis
